ClinicalTrials.gg
WithdrawnNCT05594667Updated Jul 6, 2023

Effect of SSRIs on Response to Psilocybin Therapy

A Phase 2 interventional study of Psilocybin in Depression, Major Depressive Disorder and Mild Depression, sponsored by Cybin Therapeutics Inc.. Withdrawn at 1 site in Canada. Open to participants aged 19 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-07-06.

Sponsored by Cybin Therapeutics Inc. · Phase 2, Interventional, and Treatment

Why this study was withdrawn
Funding

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
19 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 48 studies testing psilocybin in Depression — 26 open to participants now, 33 under way, 3 of them phase 3. Psilocybin · Depression.

Enrollment
47th of 48
0 · median 40
Started
2023
with 4 others
Phase 2
29 of 48
17 open now
Registered
18th of 48
by date

Among the 48 studies testing psilocybin in Depression, this one is the 47th largest by enrollment, is one of 5 that started in 2023, is one of 29 in phase 2, and was the 18th registered.

Depression

8,595 studies on the registry are indexed under Depression; 1,732 are open to participants now.

Browse Depression studies →

Open to participants now

26 of the 48 studies testing psilocybin in Depression are open now, in 7 countries. Recruiting first, the newest first:

21 more — sign in →

By country, each count listing its studies:

All 26 open studies →

About psilocybin

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,094 Depression studies recruiting now, 472 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 314 take healthy volunteers.

This study: 19 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 48 studies testing psilocybin in Depression, or all of them as a file.
02

Study summary

This study is an open-label, single-arm, within-subjects design in individuals with mild-moderate Major Depressive Disorder (MDD). All participants will receive a single dose of 25mg of psilocybin in a therapeutic setting. In order to investigate the effects of length of time on SSRI therapy, 30 participants with varying lengths of time on SSRI therapy will be enrolled, stratified into four groups:

  • Group 1: ≤ 1 year
  • Group 2: 1 to ≤ 5 years
  • Group 3: 5 to ≤ 10 years
  • Group 4: > 10 years
Read the detailed description

The majority of clinical investigations with psilocybin to date either exclude participants on SSRIs or taper them off SSRIs prior to psilocybin administration. While evidence derived from the use of larger doses of psilocybin suggests that its predominately serotonergic effects are safe when administered in controlled settings, research investigating the effects of psilocybin with individuals taking SSRIs is lacking, despite the prevalent and chronic use of SSRIs in individuals with depression.

The aim of this study is to investigate the effect of length of time on SSRIs on psilocybin-assisted therapy response in individuals with MDD. Specifically, this feasibility study investigates participants who undergo a single-dose of psilocybin (25mg) in combination with pre- and post-dose therapy sessions. The follow-up period in the present study is 12 weeks (3 months).

03

Conditions studied

  • Depression
  • Major Depressive Disorder
  • Mild Depression
  • Moderate Depression
  • Depressive Disorder

Keywords

  • Psilocybin
04

Who can participate

Ages eligible
19 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female, 19 to 65 years of age
  2. Fluent in English
  3. Currently receiving treatment with an SSRI (consistent dose for at least 6 weeks), with no changes anticipated throughout the duration of the study
  4. QIDS-SR-16 score ≥6
  5. Clinically diagnosed Major Depressive Disorder by a psychiatrist prior to screening 5a. Diagnosis defined as meeting the (Diagnostic and Statistical Manual of Mental Disorders, 5th Edition) criteria (American Psychiatric Association, 2013) for MDD
  6. MADRS score 7-34 inclusive (mild-moderate)
  7. Be medically stable as determined by screening for medical problems via a personal interview, a medical questionnaire, a physical examination, an (ECG), and routine medical blood and urinalysis laboratory tests
  8. Concurrent psychotherapy is allowed if the type and frequency of the therapy has been stable for at least two months prior to screening and is expected to remain stable during participation in the study.
  9. Agree to consume approximately the same amount of caffeine-containing beverage (e.g., coffee, tea) that he/she consumes on a usual morning, before arriving at the research unit on the mornings of the drug session day. If the participant does not routinely consume caffeinated beverages, he/she must agree not to do so on session days.
  10. Agree that for one week before the drug session, he/she will refrain from taking any nonprescription medication, nutritional supplement, or herbal supplement (specifically SAM-e, 5-HTP, L-tryptophan, St John's Wort) except when approved by the study Investigator. Exceptions will be evaluated by the Investigator and may include acetaminophen, non-steroidal anti-inflammatory drugs, and common doses of vitamins and minerals.
  11. Agree to refrain from consuming alcohol within two days prior to drug administration.
  12. Agree not to take any "as needed" medications on the morning of the drug session.
  13. Agree to use of highly effective methods of during the study (females)
  14. Normal (BMI 18.5-24.9)
  15. Own an Android or iOS device compatible with the fitness tracker software (Apple iOS 13 or higher, Android OS 7.0 or higher)
  16. Able to have a friend or family member pick them up after the dosing session
  17. Estimated (eGFR) above 40 mL/min/1.73m2 and all other blood-work values Within Normal Limits

Exclusion criteria

Exclusion Criteria:

  1. Current or past history of schizophrenia, psychotic disorder (unless substance induced or due to a medical condition), bipolar disorder, delusional disorder, dissociative disorder, paranoid personality disorder, schizoaffective disorder, borderline personality disorder, anorexia nervosa, bulimia nervosa or substance abuse, as assessed by medical history
  2. Currently diagnosed psychotic disorder in first-degree relatives, not including psychotic disorders secondary to an apparent medical reason, e.g. brain injury, dementia, or lesions of the brain, as assessed by medical history.
  3. History of seizures
  4. Uncontrolled diabetes, insulin-dependent diabetes, or history of hypoglycemia on oral hypoglycemic agent(s)
  5. Paraneoplastic syndrome
  6. History of traumatic brain injury within the last 2 years
  7. Significantly intrusive PTSD as determined by the Investigator
  8. Significant suicide risk as defined by C-SSRS within the past two years
  9. Any other cardiovascular, pulmonary, gastrointestinal, hepatic, renal, vascular or any other major concurrent illness that, in the opinion of the Investigator, may interfere with the interpretation of the study results or constitute a health risk for the participant if he/she takes part in the study
  10. Cardiovascular conditions: coronary artery disease, stroke, angina, uncontrolled hypertension, a clinically significant abnormality (e.g., atrial fibrillation), prolonged (i.e., QTc > 450msec), artificial heart valve, or in the past year
  11. Psychoactive substance use within the previous two months. 11a. The following criteria are preferred: lifetime total psychoactive substance use less than 10 times.
  12. Pregnant, nursing or breastfeeding women. Females of must be on a highly effective or double barrier method of , or abstinent.
  13. Participation in another clinical trial (currently or within the last 30 days)
  14. Current use of rifamycins (rifampin, rifabutin, rifapentine), anticonvulsants (carbamazepine, phenytoin, phenobarbital), nevirapine, efavirenz, taxol, dexamethasone); cytochrome P450 Inhibitors - including all protease inhibitors, verapamil, diltiazem, itraconazole, ketoconazole, erythromycin, clarithromycin, azithromycin, and troleandomycin; ergot alkaloids, pimozide, midazolam, triazolam, lovastatin, simvastatin, fentanyl, warfarin, metoprolol, propranolol, buspirone, tramadol, selegiline, sumatriptan.
  15. Current use of inhibitors of UGT1A9 and 1A10, monoamine oxidase inhibitors (MAOIs), Tricyclic antidepressants, aldehyde dehydrogenase inhibitors (ALDHs) and alcohol dehydrogenase inhibitors (ADHs).
  16. Use of within the past two weeks.
  17. Resting blood pressure >140 mmHg systolic and >90 mmHg diastolic at screening
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    PEX010

    25mg of PEX010 (one-time administration)

    Drug: Psilocybin

Interventions

  • 25mg of psilocybin provided by Filament Health

    Also known as: PEX010

06

What researchers measure

Primary outcomes

  1. Quick Inventory of Depressive Symptomatology-Self-Report (QIDS-SR-16)

    The QIDS-SR16 is a 16-item self-reported rating scale designed to assess severity of depressive symptoms. Scores range from 0 to 27, with higher scores indicating greater depression.

    Time frame: Baseline to end of study (week 12)

Secondary outcomes

  1. QIDS-SR-16 response

    Defined as a reduction in score of \>50%. The QIDS-SR16 is a 16-item self-reported rating scale designed to assess severity of depressive symptoms. Scores range from 0 to 27, with higher scores indicating greater depression.

    Time frame: Baseline to end of study (week 12)

  2. QIDS-SR-16 remission

    Defined as a score of ≤5. The QIDS-SR16 is a 16-item self-reported rating scale designed to assess severity of depressive symptoms. Scores range from 0 to 27, with higher scores indicating greater depression.

    Time frame: Baseline to end of study (week 12)

  3. Montgomery and Asberg Depression Rating Scale (MADRS)

    A clinician-rated interview to assess the severity of depression. Each item has a severity scale from 0 to 6, with higher scores reflecting more severe symptoms. Ratings can be added to form an overall score (from 0 to 60).

    Time frame: Baseline to end of study (week 12)

  4. Number of adverse-events (AEs)

    Number of reported AEs

    Time frame: Baseline to end of study (week 12)

  5. Number of serious adverse events (SAEs)

    Number of reported SAEs

    Time frame: Baseline to end of study (week 12)

  6. Recruitment rate

    Recruitment feasibility will be defined as a minimum recruitment rate of 70% of our target of 30 individuals within 6 months.

    Time frame: 6 months

  7. Retention

    Retention feasibility will be defined as a retention rate of 90% at study completion

    Time frame: Through study completion, an average of 6 months

Other outcomes

  1. Electroencephalography (EEG) - Response size of select ERPs (N100, P300, N400)

    The NeuroCatch® Platform is an objective, rapid neuro-physiological brain function assessment system, licensed by Health Canada as a Class II medical device. The platform provides acquisition, display, analysis, storage, reporting, and management of EEG and event related potential (ERP) information. Response size will be measured as amplitude in microvolts.

    Time frame: Baseline to end of study (week 12)

  2. Electroencephalography (EEG) - Response timing of select ERPs (N100, P300, N400)

    The NeuroCatch® Platform is an objective, rapid neuro-physiological brain function assessment system, licensed by Health Canada as a Class II medical device. The platform provides acquisition, display, analysis, storage, reporting, and management of EEG and event related potential (ERP) information. Response timing will be measured as latency in milliseconds.

    Time frame: Baseline to end of study (week 12)

  3. Heart rate variability

    Measured by the WHOOP fitness tracker device

    Time frame: 1 month (week -2 to week +2)

  4. Sleep disturbances

    Measured by the WHOOP fitness tracker device

    Time frame: 1 month (week -2 to week +2)

  5. Time in bed

    Measured by the WHOOP fitness tracker device

    Time frame: 1 month (week -2 to week +2)

  6. Respiratory rate

    Measured by the WHOOP fitness tracker device

    Time frame: 1 month (week -2 to week +2)

07

Study locations

1 site
  • Centre for Neurology Studies x Upstream
    Abbotsford, British Columbia V2T 2X5, Canada
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2023 to primary completion in Mar 2023, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 19, 2022
First posted
Oct 26, 2022
StartActual
Jan 1, 2023
Primary completionActual
Mar 14, 2023
CompletionActual
Mar 14, 2023
Last update
Jul 6, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 6, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05594667
Lead sponsor
Cybin Therapeutics Inc.
Responsible party
Sponsor
First posted
Oct 26, 2022
Start date
Jan 1, 2023
Primary completion
Mar 14, 2023
Completion
Mar 14, 2023
Last update
Jul 6, 2023

Study contacts

Reginald Peters, MD
principal investigator · Upstream

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Psilocybin

Start the discussion